Uveal melanoma (UM) is the most prevalent primary intraocular malignant tumor in adults with high mortality rate. Recently, immunotherapy has shown great success in other tumors, however, its therapeutic effect in UM is unsatisfactory, possibly due to the insufficient immune cell infiltration and low immunogenicity of UM. Thus, an efficient therapeutic strategy to reverse the immunosuppressive tumor microenvironment is required. Herein, a PD-L1 modified hierarchical structure consisting of a magnetic FeO core and spiky silica shell (MNP@Spiky/PD-L1) is developed to reverse the immunosuppressive tumor microenvironment and trigger powerful antitumor immune responses. The MNP@Spiky can induce enhanced immunogenic cell death as well as physical activation of innate immunity. First, tumor cells are disrupted directly by magnetic hyperthermia effect and released tumor-associated antigens to initiate anti-tumor immune responses. Meanwhile, the spiky surface of MNP@Spiky augmented tumor antigen uptake as well as maturation of dendritic cells through inflammasome activation. By further associating with PD-L1-targeting antibody, MNP@Spiky/PD-L1 reversed the immunosuppressive tumor microenvironment and triggered powerful antitumor immune responses. Overall, this synergistic therapeutic strategy effectively reprogramed tumor microenvironment and achieved tumor eradication, which sheds light on clinical UM immunotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/advs.202415868 | DOI Listing |
Eur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFSci Bull (Beijing)
March 2025
State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Centre for New Organic Matter, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, School of Medicine and Frontiers Science Center for Cell Responses, Nankai University, Tianjin 300071, China. Electronic address:
J Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFJ Genet Eng Biotechnol
March 2025
State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, China; Department of Hepatobiliary and Echinococcosis Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China. Electronic address:
Background: Few studies revealed that stromal genes regulate the tumor microenvironment (TME). However, identification of key-risk genes in the invasive ductal breast carcinoma-associated stroma (IDBCS) and their associations with the prediction of risk group remains lacking.
Methods: This study used the GSE9014, GSE10797, GSE8977, GSE33692, and TGGA BRCA datasets.
J Immunother Cancer
March 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!